Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For...

[cafead]

via On November 22nd, the Food and Drug Administration (FDA) approved the world’s first gene therapy for hemophilia B; Hemgenix (etranacogene dezaparvovec). Hemgenix will have a list price of $3.5 million per use. This sets a new record for the most expensive single-use gene therapy in the U.S. In spite of the very high price tag, the budgetary impact of the product for most payers will be comparatively small.

article source